These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 17345605)
1. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Lavagna A; Bergallo M; Daperno M; Sostegni R; Costa C; Leto R; Crocellà L; Molinaro G; Rocca R; Cavallo R; Pera A Inflamm Bowel Dis; 2007 Jul; 13(7):896-902. PubMed ID: 17345605 [TBL] [Abstract][Full Text] [Related]
2. Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn's disease patients treated with infliximab. Bellizzi A; Anzivino E; Ferrari F; Di Nardo G; Colosimo MT; Fioriti D; Mischitelli M; Chiarini F; Cucchiara S; Pietropaolo V J Neurovirol; 2011 Aug; 17(4):303-13. PubMed ID: 21547609 [TBL] [Abstract][Full Text] [Related]
3. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577 [TBL] [Abstract][Full Text] [Related]
4. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Scott FI; Osterman MT; McConnell RA; Lorusso M; Aberra F; Kerner C; Lichtenstein GR; Lewis JD Inflamm Bowel Dis; 2013 Nov; 19(12):2625-33. PubMed ID: 24108113 [TBL] [Abstract][Full Text] [Related]
5. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Torre-Cisneros J; Del Castillo M; Castón JJ; Castro MC; Pérez V; Collantes E Rheumatology (Oxford); 2005 Sep; 44(9):1132-5. PubMed ID: 15927999 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301 [TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Reijasse D; Le Pendeven C; Cosnes J; Dehee A; Gendre JP; Nicolas JC; Beaugerie L Inflamm Bowel Dis; 2004 Mar; 10(2):85-90. PubMed ID: 15168806 [TBL] [Abstract][Full Text] [Related]
8. [Indications and results of infliximab in Crohn's disease]. Karoui S; Boubaker J; Filali A Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505 [TBL] [Abstract][Full Text] [Related]
10. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia. Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386 [TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. Hradsky O; Copova I; Zarubova K; Durilova M; Nevoral J; Maminak M; Hubacek P; Bronsky J Dig Dis Sci; 2015 Nov; 60(11):3399-407. PubMed ID: 26091801 [TBL] [Abstract][Full Text] [Related]
12. JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France. Mengelle C; Kamar N; Mansuy JM; Sandres-Sauné K; Legrand-Abravanel F; Miédougé M; Rostaing L; Izopet J J Med Virol; 2011 Jan; 83(1):132-6. PubMed ID: 21108350 [TBL] [Abstract][Full Text] [Related]
13. Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab. Giannecchini S; Clausi V; Vultaggio A; Macera L; Maggi F; Martelli F; Azzi A; Maggi E; Matucci A J Neurovirol; 2012 Feb; 18(1):55-61. PubMed ID: 22281875 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of Crohn's disease by infliximab. About 20 cases]. Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377 [TBL] [Abstract][Full Text] [Related]
16. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. Yao K; Gagnon S; Akhyani N; Williams E; Fotheringham J; Frohman E; Stuve O; Monson N; Racke MK; Jacobson S PLoS One; 2008 Apr; 3(4):e2028. PubMed ID: 18446218 [TBL] [Abstract][Full Text] [Related]
17. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. Ling PD; Lednicky JA; Keitel WA; Poston DG; White ZS; Peng R; Liu Z; Mehta SK; Pierson DL; Rooney CM; Vilchez RA; Smith EO; Butel JS J Infect Dis; 2003 May; 187(10):1571-80. PubMed ID: 12721937 [TBL] [Abstract][Full Text] [Related]
18. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684 [TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601 [TBL] [Abstract][Full Text] [Related]
20. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Seishima M; Yamanaka S; Fujisawa T; Tohyama M; Hashimoto K Br J Dermatol; 2006 Aug; 155(2):344-9. PubMed ID: 16882173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]